The Board of Directors of Dicot Pharma AB (“Dicot Pharma” or the “Company”) intends, subject to authorization by the Annual General Meeting on 6 May 2026, to resolve on a rights issue of units, consisting of shares and warrants, of approximately SEK 210 million (the “Rights Issue”) to finance the planned phase 2b study with the drug candidate LIB-01. The Rights Issue is pre-committed to approximately 80 percent, corresponding to approximately SEK 168 million, through subscription undertakings from existing shareholders, board and management, and guarantee commitments from Schonfeld Global Master Fund LP and Anavio Capital Partners LLP, among others. The net proceeds are intended primarily to finance the execution of the clinical phase 2b study with LIB-01.

Dicot Pharma’s full press release can be found here.

Background and rationale
Dicot Pharma is developing the drug candidate LIB-01 as a novel treatment concept for erectile dysfunction, with the ambition of surpassing currently available drugs. LIB-01 demonstrates a unique long-acting effect on erectile function, a favourable safety profile and a new mechanism of action that clearly differs from today’s erectile dysfunction drugs, acting in part through the melanocortin system via the MC4 receptor. Previous research also indicates effects on premature ejaculation, and ongoing preclinical work is investigating parameters linked to metabolic diseases.

Following an evaluation of various financing alternatives, the Board of Directors has concluded that a rights issue prioritizing existing shareholders, while also enabling external investors to participate through guarantee commitments, is preferable from a shareholder perspective and supports the Company’s ambition to enter into industrial partnerships and out-licensing agreements ahead of phase 3. The amount pre-committed corresponds to a fully financed phase 2b study.

The net proceeds from the Rights Issue are intended to finance, in order of priority: execution of the clinical phase 2b study including preclinical studies ahead of phase 3 (approximately 75 percent), other R&D and scale-up of the manufacturing process (approximately 15 percent), and business development, patents, regulatory processes and corporate governance (approximately 10 percent).

Key terms
‍The Rights Issue is pre-committed to approximately 80 percent through subscription undertakings of approximately SEK 17.7 million (corresponding to approximately 8.4 percent) from larger existing shareholders, members of the Board of Directors and members of management, and guarantee commitments of approximately SEK 150.3 million (corresponding to approximately 71.6 percent) from Schonfeld Global Master Fund LP, Anavio Capital Partners LLP and Vator Securities. Each unit is preliminarily comprised of 4 shares and 1 warrant, with the warrants intended to be exercisable during the second quarter of 2027 at a strike price within the range of 100–150 percent of the subscription price in the Rights Issue. The subscription price is intended to be set at a discount of approximately 25 percent to the theoretical ex-rights price (TERP). The complete terms and conditions are expected to be resolved by the Board of Directors on or around 8 May 2026, with the subscription period expected to commence in May 2026.

About Dicot Pharma
Dicot Pharma is developing the drug candidate LIB-01, intended to be a potency agent for the treatment of erectile dysfunction and premature ejaculation, with the ambition of providing significantly longer effect and far fewer side effects compared to currently available drugs. The global market for these sexual dysfunctions is estimated at USD 8 billion, with more than 500 million men affected. Dicot Pharma’s business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market. The Company is listed on Nasdaq First North and has approximately 16,750 shareholders.

Corpura is acting as Sole Global Coordinator and Sole Bookrunner in connection with the Rights Issue.

For more information contact:
Alexander Kangas
Phone: +46 (0)72-252 34 51
Email: alexander.kangas@corpura.se

‍